Trial Profile
A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2022
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary) ; Nazartinib (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Feb 2022 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 31 Jan 2022 Status changed from completed to discontinued.
- 20 May 2021 Status changed from active, no longer recruiting to completed.